However, a pre-specified subgroup efficacy analysis of this trial recently reported greater efficacy in patients with FGFR2b overexpression (2+/3+ staining) in >10% of tumour cells compared to the overall population [117], consistent with the emerging paradigm that tumours with homogeneous or high-level FGFR2 overexpression are the most likely to benefit from FGFR2-targeted therapies. The gene discussed is FGFR2; the disease is neoplasm.